JPRN-UMIN000012514尚未招募2 期
A phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous Non- Small Cell Lung Cancer with brain metastasis and Harboring Epidermal Growth Factor Receptor Mutations. - A phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous Non- Small Cell Lung Cancer with brain metastasis and Harboring Epidermal Growth Factor Receptor Mutations.
Department of Respiratory Medicine, Kumamoto University Hospital0 个研究点目标入组 16 人开始时间: 2013年12月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Squamous cell carcinoma 2)Interstitial pneumonia or pulmonary fibrosis on chest CT scans 3)History of EGFR-TKI, VEGF antibody allergic reaction. 4)Brain metastasis expected bleeding 5)Radiotherapy enforcement example for the brain 6)Active severe comorbidity disease. 7)History of hemoptysis 8)Uncontrollable hypertension 9)History of gastrointenstinal perforation or diverticulitis or fistula 10)Scheduled operation 11)Active concomitant malignancy 12)Pregnant or breast-feeding females 13)Inappropriate patients for this study judged by the physicians
研究者
相似试验
已完成
2 期
A phase II study of erlotinib plus bevacizumab in patients with performance status 2 to 3 and EGFR mutation-positive advanced non-small-cell lung cancerJPRN-UMIN000016507Shizuoka cancer center21
已完成
不适用
A phase II study of erlotinib plus bevacizumab in chemo-naive patients aged 75 or older with advanced non-squamous non-small-cell lung cancer harboring sensitive EGFR gene mutations(HSR1501)Advanced non-squamous non-small-cell lung cancerJPRN-UMIN000016904Department of Internal medicine, second division, Hamamatsu Univ. School of Medicine26
招募中
2 期
Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer not harboring EGFR mutation who failed to prior treatment (TAILORED-2 study)on-Small Cell Lung CancerJPRN-UMIN000006459Kyushu University38
招募中
2 期
Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer harboring EGFR mutation who acquired resistance to prior gefitinib treatment (TAILORED-1 study)on-Small Cell Lung CancerJPRN-UMIN000006457Kyushu University30
已完成
2 期
Phase II study of erlotinib plus bevacizumab and inserted cisplatin, pemetrexed plus bevacizumab as a 1st-line treatment for advanced non-squamous, non-small cell lung cancer harboring activating EGFR mutationsadvanced EGFR mutation-positive non-squamous non-small cell lung cancerJPRN-UMIN000015467Department of Thoracic Oncology Osaka Medical Center for Cardiovascular diseases20